Key clinical point: ASCO and Friends of Cancer have submitted draft recommendations to the FDA for expanding cancer clinical trial participation.
Major finding: The organizations recommend addressing minimum age requirements, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.
Data source: Draft guidance produced by ASCO and Friends of Cancer Research and submitted to the FDA.
Disclosures: Individual members of the working groups were not listed and conflicts of interest were not disclosed.
Friends of Cancer and ASCO letter to the FDA.
This Week's Must Reads
RNA expression offers potential biomarker in hemophilia A, Niloofar N et al. Hematology. 2019;24(1):255-62
Caplacizumab speeds platelet normalization, Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311
Remote area of Canada provides pool for genetic research, Scully M-F et al. Transfus Apher Sci. 2018 Dec;57(6):713-6
Can web tools replace pharmacokinetic analysis in hemophilia A?, Nagao A et al. Thromb Res. 2019 Jan;173:79-84
BSH issues recommendations for glucocorticoid use in ITP, Hill QA et al. Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15735
Must Reads in Business of Medicine
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P
Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.